- Active not recruitingPHASE1
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
This study looks at a new treatment called remzistotug for advanced cancers that haven't responded to usual treatments. It's the first time it will be tested in people to check if it's safe and how it works in the body.
For: NeoplasmsUnited States · Australia · Canada - Active not recruitingPHASE2
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
This study is looking at new combinations of medicines for advanced lung cancer that hasn't been treated before. We want to see how safe these new treatments are and how well they work together. It's for people whose cancer shows high levels of a specific marker called PD-L1.
For: Lung Cancer, Non-Small CellUnited States · Argentina · Belgium - Active not recruitingPHASE3
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
This study is looking at a new combination of medicines, belrestotug and dostarlimab, for people with a certain type of lung cancer that hasn't been treated before. It compares this combination to a standard treatment (pembrolizumab) and a dummy drug (placebo).
For: Lung Cancer, Non-Small CellUnited States · Argentina · Belgium - Active not recruitingPHASE1
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
This study is testing new medicines for advanced cancers that have grown. It particularly looks at how safe these new drugs are and how well they work, both alone and with existing treatments. The research also wants to understand how the body uses these new drugs.
For: NeoplasmsUnited States · Canada · Japan